1
Addressing unmet medical needs
2
Exploring innovative technologies and treatment approaches
3
Improving the lives of patients worldwide
Unified by three key principles across the organization, our goal is a common one: addressing unmet medical needs, exploring innovative technologies and treatment approaches, and improving the lives of patients worldwide.
Since 1981, we have been recognized for developing pioneering treatments for rare diseases. Today, as the specialty care global business unit of Sanofi, we remain focused on developing these highly specialized treatments for patients and have extended our portfolio to include rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology.
An innovator in RARE DISEASES
Focusing on uncommon and underserved medical conditions, our Rare Disease franchise is committed to empowering the lives of patients with rare diseases by offering sustainable, transformative healthcare options.
Committed to RARE BLOOD DISORDERS
We are committed to significantly improving the health and lives of people with rare blood disorders around the world through groundbreaking science.
A leader in MULTIPLE SCLEROSIS
We are committed to being a long-term partner to the multiple sclerosis (MS) community by working to deliver scientific advancements that will have a significant impact on the unmet needs of people living with MS.
Advancing our pipeline in ONCOLOGY
We have a strong heritage in oncology and are working to expand our contributions in the treatment of cancer by building a pipeline of future treatments in immuno-oncology through our own research and partnerships.
Researching new treatments in IMMUNOLOGY
Expanding our research focus, we are targeting unmet needs in immune diseases including atopic dermatitis, rheumatoid arthritis, asthma, nasal polyposis, and eosinophilic esophagitis.
Our research pipeline
Explore our pipeline to see highlights of our research programs in various stages of clinical development.
Portfolio of products
We have a specialized portfolio of 25+ products globally across our four therapeutic areas.
